| Literature DB >> 35051046 |
Tina Elersek1, Matjaž Novak1, Mateja Mlinar1, Igor Virant2, Nika Bahor1,3, Karin Leben1,3, Bojana Žegura1, Metka Filipič1.
Abstract
Tyrosine kinase inhibitors (TKIs) are designed for targeted cancer therapy. The consumption of these drugs during the last 20 years has been constantly rising. In the zebrafish (Danio rerio) embryo toxicity test, we assessed the toxicity of six TKIs: imatinib mesylate, erlotinib, nilotinib, dasatinib, sorafenib and regorafenib. Imatinib mesylate and dasatinib induced lethal effects, while regorafenib, sorfenib and dasatinib caused a significant increase of sub-lethal effects, predominantly oedema, no blood circulation and formation of blood aggregates. The analyses of the changes in the expression of selected genes associated with the hormone system after the exposure to imatinib mesylate, dasatinib and regorafenib demonstrated that all three tested TKIs deregulated the expression of oestrogen receptor esr1, cytochrome P450 aromatase (cypa19b) and hydroxysteroid-dehydrogenase (hsd3b), regorafenib, and also thyroglobulin (tg). The expression of genes involved in the DNA damage response (gadd45 and mcm6) and apoptosis (bcl2) was deregulated only by exposure to regorafenib. The data indicate that common mechanisms, namely antiangiogenic activity and interference with steroidogenesis are involved in the TKI induced sub-lethal effects and potential hormone disrupting activity, respectively. The residues of TKIs may represent an environmental hazard; therefore, further ecotoxicological studies focusing also on the effects of their mixtures are warranted.Entities:
Keywords: aquatic toxicity; environmental hazard; gene expression; tyrosine kinase inhibitors; zebrafish embryo toxicity test
Year: 2021 PMID: 35051046 PMCID: PMC8781212 DOI: 10.3390/toxics10010004
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Selected tyrosine kinase inhibitors and their kinase targets.
| Compound | Kinase Target |
|---|---|
| Imatinib mesylate | BCR-ABL, PDGFR, c-KIT |
| Erlotinib | EGFR |
| Nilotinib | BCR-ABL, PDGFR, DDR1 |
| Sorafenib | VEGFR2, PDGFR, KIT, FLT3, BRAF |
| Dasatinib | BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, PDGFRβ |
| Regorafenib | VEGFR, PDGFR, BRAF, RAF-1, KIT, Ret, TIE-2, FGFR |
Note: BCR-ABL, breakpoint cluster region gene-Abelson proto-oncogene fusion protein; EGFR, epidermal growth factor receptor; SRC, proto-oncogene tyrosine-protein kinase Src; LCK, lymphocyte cell-specific protein-tyrosine kinase; YES, proto-oncogene tyrosine-protein kinase Yes; FYN, proto-oncogene tyrosine-protein kinase Fyn; c-KIT, proto-oncogene tyrosine-protein kinase Kit; EPHA2, ephrin type-A receptor 2; PDGFR (α/β), platelet-derived growth factor receptor (α/β); BTK, Bruton’s tyrosine kinase; DDR1, discoidin domain receptor family, member 1; VEGFR (1/2/3), vascular endothelial growth factor receptor (1/2/3); RAF, proto-oncogene serine/threonine-protein kinase; RET, proto-oncogene tyrosine-protein kinase receptor Ret; FGFR-1/2, fibroblast growth factor receptor 1/2; TIE-2, angiopoietin-1 receptor; FLT3, fms-like tyrosine kinase 3; BTAF, serine-threonine kinase.
Figure 1Consumption of tyrosine kinase inhibitors in Slovenia from 2010 to 2019. The numbers above the columns represent the number of registered TKIs per year.
Figure 2Lethality of the selected tyrosine kinase inhibitors in zebrafish embryo test after 48 and 96 h exposure. ERLO was tested in the concentration range 1.9–200 mg/L (a), IMAT 2.3–239 mg/L (b), NILO 0.6–67 mg/L (c), DASA 0.6–60 mg/L (d), REGO 0.06–6 mg/L (e), and SORA 0.6–60 mg/L (f). * indicates the statistical difference compared to the negative control (tested with ANOVA). p indicates the precipitation of the compound in the treatment medium.
Figure 3Sub-lethal effects of the selected tyrosine kinase inhibitors after 48 (light grey) and 96 h exposure (dark grey). Results are presented as mean percentage (±SE) of sub-lethal and teratogenic effects from three independent experiments. Percentage of sub-lethal effect and statistical comparisons were calculated considering all embryos per drug concentration (60 embryos from three experiments). A statistically significant increase in the percentage of sub-lethal effects compared to the negative control (ANOVA) is indicated by *. The letter p indicates precipitation of the compound in the treatment medium.
Figure 4The incidence (%) of observed sub-lethal (lack of blood circulation, oedema and blood aggregates) and teratogenic effects (tail deformity) in zebrafish embryos after 96 h of exposure to SORA, REGO and DASA. Percentage of sub-lethal effect and statistical comparisons were calculated considering all embryos per drug concentration (60 embryos from three experiments). Data are presented as mean percentage (±SE) of observed sub-lethal effects from three independent experiments.
Figure 5Hatching rate in zebrafish embryos after 96 h exposure to the selected TKI. Results are presented as mean values of percentage of embryos hatched ± SD. Percentage of hatched embryos and statistical comparisons were calculated considering all embryos per drug concentration (60 embryos from three experiments). Statistical difference from the control (ANOVA) is indicated by *.
Effects of IMAT, REGO and DASA on mRNA expression of selected genes in exposed zebrafish embryos. Results are expressed as relative mRNA expression levels normalized to the corresponding control. Data are means ± SD of three independent experiments with two technical duplicates. Significant differences (p ≤ 0.05) between treated and non-treated embryos are marked with *. Genes that were deregulated ≥ 1.5-fold compared to the corresponding control are marked in bold.
| Gene | REGO | DASA | IMAT | |||
|---|---|---|---|---|---|---|
| Symbol | 0.2 mg/L | 0.6 mg/L | 0.2 mg/L | 0.6 mg/L | 2.3 mg/L | 210 mg/L |
|
|
|
| 1.26 ± 0.37 | 0.74 ± 0.18 | 0.72 ± 0.01 * | 1.27 ± 0.33 |
|
| 0.99 ± 0.12 | 0.92 ± 0.13 | 1.02 ± 0.13 | 0.98 ± 0.18 | 0.95 ± 0.07 | 1.16 ± 0.19 |
|
| 0.99 ± 0.12 | 0.85 ± 0.14 | 0.91 ± 0.12 | 0.88 ± 0.08 | 0.94 ± 0.09 | 0.98 ± 0.16 |
|
| 1.05 ± 0.08 | 0.98 ± 0.12 | 1.00 ± 0.07 | 0.91 ± 0.12 | 0.86 ± 0.14 | 0.92 ± 0.08 |
|
| 0.95 ± 0.13 | 0.69 ± 0.15 * | 1.05 ± 0.23 | 1.11 ± 0.06 | 0.94 ± 0.19 | 0.74 ± 0.18 |
|
| 1.14 ± 0.36 |
| 1.07 ± 0.39 | 1.13 ± 0.18 | 1.17 ± 0.05 |
|
|
|
|
| 0.96 ± 0.30 |
|
|
|
|
|
|
|
|
|
| 1.21 ± 0.35 |
|
| 1.06 ± 0.39 | 1.15 ± 0.21 | 1.07 ± 0.43 | 0.89± 0.08 | 1.31 ± 0.65 | 1.32 ± 0.20 |
|
| 1.09 ± 0.03 | 0.89 ± 0.15 | 1.07 ± 0.43 | 0.98 ± 0.08 | 1.07 ± 0.29 | 1.16 ± 0.30 |
|
|
|
| 0.68 ± 0.10 |
|
|
|
|
| 0.86 ± 0.34 | 1.13 ± 0.52 | 1.13 ± 0.41 | 0.82 ± 0.16 | 0.94 ± 0.06 | 0.96 ± 0.30 |
|
|
| 0.95 ± 0.37 | 1.14 ± 0.42 | 1.10 ± 0.52 | 0.86 ± 0.05 | 1.01 ± 0.10 |
|
| 0.86 ± 0.14 |
| 0.96 ± 0.11 | 0.89 ± 0.07 | 0.78 ± 0.17 | 0.78 ± 0.05 |
|
| 0.89 ± 0.11 | 0.74 ± 0.02 | 0.97 ± 0.03 | 0.84 ± 0.06 | 1.05 ± 0.15 | 1.03 ± 0.10 |
|
| 0.95 ± 0.18 |
| 1.02 ± 0.03 | 0.72 ± 0.05 * | 0.95 ± 0.14 | 0.90 ± 0.17 |
|
| 1.19 ± 0.39 | 1.09 ± 0.37 | 1.03 ± 0.45 | 0.73 ± 0.001 | 0.95 ± 0.29 | 1.13 ± 0.20 |
|
| 0.87 ± 0.20 | 0.69 ± 0.13 | 1.05 ± 0.05 | 0.86 ± 0.08 | 0.77 ± 0.18 | 0.67 ± 0.10 |
|
| 1.01 ± 0.07 | 0.73 ± 0.05 | 1.00 ± 0.11 | 0.96 ± 0.15 | 0.80 ± 0.17 | 0.95 ± 0.32 |